Quest Diagnostics Inc (NYSE:DGX) has earned a consensus rating of “Hold” from the twenty-three analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $104.92.

Several research analysts have weighed in on DGX shares. KeyCorp reiterated a “hold” rating on shares of Quest Diagnostics in a report on Friday, October 27th. ValuEngine upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Wells Fargo & Company lowered their price target on Quest Diagnostics from $88.00 to $86.00 and set a “market perform” rating on the stock in a research report on Friday, October 20th. Goldman Sachs Group downgraded Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and lowered their price target for the stock from $121.00 to $113.00 in a research report on Tuesday, October 10th. Finally, Canaccord Genuity boosted their price objective on Quest Diagnostics from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, October 26th.

In related news, Chairman Stephen H. Rusckowski sold 59,235 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $108.16, for a total value of $6,406,857.60. Following the completion of the sale, the chairman now directly owns 220,049 shares in the company, valued at $23,800,499.84. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.75% of the company’s stock.

Several hedge funds have recently modified their holdings of DGX. WFG Advisors LP boosted its stake in shares of Quest Diagnostics by 45.3% in the second quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock valued at $107,000 after buying an additional 301 shares during the period. Sun Life Financial INC boosted its stake in shares of Quest Diagnostics by 14,142.9% in the second quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock valued at $111,000 after buying an additional 990 shares during the period. Parallel Advisors LLC boosted its stake in shares of Quest Diagnostics by 0.9% in the second quarter. Parallel Advisors LLC now owns 1,291 shares of the medical research company’s stock valued at $140,000 after buying an additional 12 shares during the period. Acrospire Investment Management LLC boosted its stake in shares of Quest Diagnostics by 300.0% in the second quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock valued at $178,000 after buying an additional 1,200 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in Quest Diagnostics during the second quarter valued at approximately $180,000. Institutional investors and hedge funds own 89.20% of the company’s stock.

Quest Diagnostics (NYSE:DGX) traded up $0.47 during trading hours on Monday, hitting $97.09. The stock had a trading volume of 764,400 shares, compared to its average volume of 1,022,508. Quest Diagnostics has a 1-year low of $89.46 and a 1-year high of $112.96. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.37. The company has a market cap of $13,230.00, a price-to-earnings ratio of 17.40, a P/E/G ratio of 2.02 and a beta of 0.60.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The business had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.92 billion. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. The firm’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the company earned $1.37 EPS. sell-side analysts predict that Quest Diagnostics will post 5.65 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 9th will be paid a $0.45 dividend. This represents a $1.80 annualized dividend and a dividend yield of 1.85%. The ex-dividend date of this dividend is Monday, January 8th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 37.50%.

WARNING: “Quest Diagnostics Inc (DGX) Given Consensus Rating of “Hold” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/11/quest-diagnostics-inc-dgx-given-consensus-rating-of-hold-by-analysts.html.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.